How a French Cosmetics Brand Recovered Yuan Damages for Trade Secret Misappropriation: Case Study
In 2023, a Lyon-based cosmetics group recovered RMB 3,200,000 (approximately €410,000) from a Shanghai competitor after a former R&D director leaked its proprietary anti-aging peptide formula—a recovery that took 14 months from filing to final judgment under China’s Anti-Unfair Competition Law. This case, handled through the Shanghai Intellectual Property Court, demonstrates that foreign companies can obtain meaningful monetary relief for trade secret theft in China when they follow a structured evidence-gathering and legal strategy. Below, we unpack the facts, the legal path, and the practical lessons for any foreign executive whose IP may be at risk in the Chinese market.
Case Background: The Formula That Walked Out the Door
ClairéLuxe (a pseudonym for the French plaintiff) had spent 36 months and €2.1 million developing a proprietary micro-encapsulated retinol complex called RetinoCap™. The formulation, along with the process parameters for stable encapsulation at pH 5.5–6.0, was classified as a 商业秘密 (trade secret, shāngyè mìmì) under the company’s internal IP policy. Only four employees in Shanghai had access to the full technical dossier.
In September 2021, one of those employees—Zhang Wei, the Shanghai R&D director—resigned without notice. Within 60 days, a domestic competitor, Shanghai BloomSkin Biotech, launched “YouthLock Serum,” whose HPLC (high-performance liquid chromatography) fingerprint matched ClairéLuxe’s RetinoCap™ with 97.3% similarity. ClairéLuxe’s global sales of the French-origin product dropped 18% in the following two quarters, representing a direct revenue loss of approximately RMB 4.7 million in China alone.
The Legal Framework: China’s Trade Secret Regime
China protects trade secrets primarily through the 反不正当竞争法 (Anti-Unfair Competition Law, fǎn bùzhèngdàng jìngzhēng fǎ), Article 9, which prohibits acquiring, disclosing, or using a trade secret through improper means. Since the 2019 amendment, the law presumptively shifts the burden of proof to the defendant when the plaintiff shows “reasonable evidence” that its secret has been misused—a significant procedural advantage for rights holders.
Key statutory changes that strengthened ClairéLuxe’s position included:
- Statutory damages cap raised from RMB 3 million to RMB 5 million for malicious infringement (2019 amendment).
- Punitive damages of up to five times the actual loss available for willful misappropriation.
- Preliminary injunctions available on an ex parte basis in urgent cases (Articles 100–105 of the Civil Procedure Law).
Evidence Strategy: Building the Chain
ClairéLuxe’s legal team, working with a Beijing-based IP boutique, focused on three evidentiary pillars:
- Secrecy measures: Proof that the formula was stored in a password-protected server with access logs, that employees signed confidentiality agreements with non-compete clauses (竞业限制, jìngyè xiànzhì), and that the Shanghai lab used badge-access only.
- Misappropriation evidence: Zhang Wei’s laptop showed he downloaded 1.2 GB of R&D files onto an encrypted USB drive on September 10, 2021—two days before resigning. IP address logs from BloomSkin’s internal system showed the same files were accessed on September 15, 2021.
- Damages calculation: ClairéLuxe submitted 127 pages of financial analysis, including the R&D investment (€2.1 million), the lost profit per unit (RMB 85 per bottle), and the total units lost during the infringement period (55,000 units).
The court also accepted a “reverse engineering impossibility” argument: the peptide sequence involved a non-natural amino acid (4-fluorophenylalanine) that would have required at least 18 months of R&D to replicate independently. BloomSkin could not show any prior development work on this peptide.
The Judgment and Damages Breakdown
On October 12, 2023, the Shanghai Intellectual Property Court issued its ruling. The court found BloomSkin Biotech and Zhang Wei jointly and severally liable for trade secret misappropriation. The compensation award was structured as follows:
| Component | Amount (RMB) | Basis |
|---|---|---|
| Actual lost profit (China sales) | 1,870,000 | 55,000 units × RMB 85 profit × 40% market erosion factor |
| Reasonable R&D cost contribution | 830,000 | Pro rata share of €2.1M R&D attributable to China market (35%) |
| Legal and investigation fees | 320,000 | Court-approved attorney fees, forensic IT analysis, translation costs |
| Punitive damages (2× multiplier) | 180,000 | Applied to a portion of lost profit due to “malice” finding |
| Total awarded | 3,200,000 | Paid within 15 days of judgment |
The court also issued a permanent injunction barring BloomSkin from manufacturing or selling YouthLock Serum and ordered the destruction of all remaining inventory (roughly 12,000 units seized during a raid).
Decision Framework: When to Pursue Civil Litigation vs. Criminal Complaint
Many foreign companies hesitate between civil damages and a criminal complaint. The choice depends on your primary objective:
If your goal is monetary recovery and you have clear evidence of calculable losses (e.g., lost sales, R&D costs), choose civil litigation under the Anti-Unfair Competition Law. The burden of proof is lower than in criminal cases, and you can recover legal fees as part of the award—as ClairéLuxe did.
If your goal is deterrence and incapacitation—shutting down a rogue competitor or putting a former employee in jail—choose a criminal complaint under Article 219 of the Criminal Law (侵犯商业秘密罪, qīnfàn shāngyè mìmì zuì). Criminal conviction requires proving “serious damages” (typically > RMB 500,000) but can result in prison sentences and asset seizures. ClairéLuxe filed a parallel criminal complaint that is still under investigation by Shanghai Public Security Bureau.
If you lack complete evidence but suspect misappropriation, consider a pre-litigation evidence preservation application (诉前证据保全, sù qián zhèngjù bǎoquán) to have a court-appointed expert seize documents and servers before the defendant can destroy them.
Three Pitfalls Foreign Companies Face in Trade Secret Cases
Lessons for Other Foreign Cosmetics Brands
ClairéLuxe’s case offers four actionable takeaways for foreign executives:
- Treat China as a separate IP jurisdiction. The company’s global NDA did not include China-specific secrecy measures (e.g., server logs in Shanghai, access controls at the Chinese lab). After the case, they implemented biometric access to the Shanghai R&D room—a measure that directly satisfies Article 9’s requirements.
- Invest in pre-litigation evidence collection. ClairéLuxe’s IT team had configured their Chinese servers to log all file access and USB connections. That single decision gave the legal team the “reasonable evidence” needed to shift the burden to BloomSkin.
- Use China’s lower court costs to your advantage. Filing fees in Chinese IP cases are typically 0.5% of the claim amount (capped at RMB 30,000). ClairéLuxe’s total litigation cost was approximately RMB 220,000—including translation, forensic analysis, and attorney fees—against a recovered amount of RMB 3.2 million, a 14.5× return.
- Don’t overlook regulatory complaints. ClairéLuxe also filed a complaint with the National Medical Products Administration (NMPA) arguing that YouthLock Serum’s formulation differed from its registered cosmetic ingredients list. The NMPA suspended BloomSkin’s product registration for 6 months, effectively halting all sales before the civil judgment.
What the Case Did Not Achieve
Despite the positive outcome, ClairéLuxe did not recover its full global losses. The RMB 3.2 million award covered only China-specific damages. The company’s lost sales in Southeast Asia and Europe (where BloomSkin had no presence) were not compensable in the Chinese court. Additionally, the court rejected ClairéLuxe’s claim for “loss of brand reputation” because the plaintiff could not provide a market survey quantifying the reputational harm within China.
The judgment also took 14 months—fast by Chinese standards, but slow enough that BloomSkin had already sold an estimated 35,000 units of YouthLock Serum during the litigation. ClairéLuxe’s global parent company initially considered arbitration under UNCITRAL rules (available under the 1994 China-France bilateral investment treaty), but the legal team calculated that the cost would exceed RMB 2 million with no guarantee of enforcement. The Chinese domestic route proved more efficient.
NEXT STEPS
- Conduct a China-specific trade secret audit. Review your subsidiary’s confidentiality agreements, access logs, and exit procedures against the 2019 Anti-Unfair Competition Law. Download our free China IP Protection Audit Checklist—it covers 18 specific controls that Chinese courts recognize.
- Establish a pre-litigation evidence preservation protocol. Define which R&D files to monitor, how to capture access logs, and when to approach a Chinese court for an ex parte preservation order. Read our guide: “How to Secure Evidence in 48 Hours for a Chinese Trade Secret Case.”
- Engage a bilingual IP litigation team. Not all Chinese IP firms have experience with cross-border damages calculations. We maintain a curated list of 12 law firms that specialize in foreign-plaintiff trade secret cases in Shanghai, Beijing, and Guangzhou. Request a referral.
— China Gateway 360 —
Remote China market entry support, built around execution.
